Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
HIV is characterized by frequent immune system activation. Early in the course of infection
the body establishes an immune activation "set point" related to the amount of HIV in the
blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with
very low levels of CD4 cells, the body cannot fight off illness. This is known as
immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS.
Evidence suggests that by decreasing the rate of immune system activation, immune deficiency
progression could be prevented. The purpose of this study is to learn how well chloroquine
can reduce the level of immune activation and to test the safety and tolerance of chloroquine
in people infected with HIV.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)